Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$7.03
+7.7%
$4.98
$1.39
$7.19
$1.30B2.247.50 million shs7.28 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.86
+3.2%
$9.45
$6.28
$18.49
$3.68B0.08225,387 shs62,274 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$54.36
-0.1%
$51.70
$23.30
$66.06
$3.37B2.221.33 million shs309,887 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.46
-0.8%
$33.40
$22.96
$43.15
$3.65B0.722.76 million shs612,571 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
+25.10%+26.80%+37.18%+83.94%+363.12%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+1.25%-5.31%-6.41%+63.61%-37.04%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.79%-8.63%+7.96%+14.12%+68.44%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.28%-1.73%-9.40%+4.03%+14.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$7.03
+7.7%
$4.98
$1.39
$7.19
$1.30B2.247.50 million shs7.28 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.86
+3.2%
$9.45
$6.28
$18.49
$3.68B0.08225,387 shs62,274 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$54.36
-0.1%
$51.70
$23.30
$66.06
$3.37B2.221.33 million shs309,887 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.46
-0.8%
$33.40
$22.96
$43.15
$3.65B0.722.76 million shs612,571 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
+25.10%+26.80%+37.18%+83.94%+363.12%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+1.25%-5.31%-6.41%+63.61%-37.04%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.79%-8.63%+7.96%+14.12%+68.44%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+1.28%-1.73%-9.40%+4.03%+14.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
2.00
Hold$10.0042.23% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.78
Moderate Buy$21.1394.61% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.574.08% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.85
Moderate Buy$95.50203.59% Upside

Current Analyst Ratings Breakdown

Latest SLS, VKTX, TLX, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
5/1/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Reiterated RatingBuy$125.00
4/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Set Price Target$95.00
4/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Lower Price TargetOverweight$105.00 ➝ $100.00
4/27/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
UpgradeStrong-Buy
4/21/2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
Reiterated RatingSell (D-)
4/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Reiterated RatingSell (D)
4/20/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Reiterated RatingSell (D-)
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/A$0.46 per shareN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.58$0.04 per share246.42$1.23 per share8.83
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M8.99N/AN/A$7.31 per share7.44
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$26.86M-$0.25N/AN/AN/AN/A-61.95%-54.48%N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A63.85N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)

Latest SLS, VKTX, TLX, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.06-$0.05+$0.01-$0.05N/AN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
4/29/2026Q1 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.01-$1.37-$0.36-$1.37N/AN/A
3/19/2026Q4 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.0633-$0.05+$0.0133-$0.05N/AN/A
2/20/2026H2 2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$0.0493-$0.01-$0.0593-$0.0070$421.50 million$206.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
10.72
10.72
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.08
1.43
1.27
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
10184.53 million181.95 millionNot Optionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.11 millionN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.11 million109.95 millionOptionable

Recent News About These Companies

LGND: 1Q:26 Results Highlight Breadth of Portfolio
HC Wainwright Brokers Decrease Earnings Estimates for VKTX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$7.03 +0.50 (+7.67%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.86 +0.34 (+3.18%)
As of 12:39 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$54.36 -0.03 (-0.06%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$31.46 -0.24 (-0.77%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.